secwatch.observer — SEC 8-K summary
======================================

Issuer:     CDT Equity Inc. (CDT)
CIK:        0001896212
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001493152-24-014883
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Conduit Pharmaceuticals restates 2023 quarterly results on legal expense miscapitalization; non-reliance
--------------------------------------------------------------------------------

- Previously issued unaudited financials for Q1, Q2, Q3 2023 should no longer be relied upon due to misclassification of legal expenses.
- Legal expenses related to business combination and PIPE financing were expensed but should have been capitalized, reducing quarterly expenses by $493k, $402k, $639k respectively.
- Restatement adjustments understated net income (loss), understated prepaid expenses, and overstated additional paid-in capital; deemed material individually and in aggregate.
- Company will incorporate the corrections in footnotes of its upcoming 10-K annual report; discussed with auditor Marcum LLP.
- Marcum LLP has provided a letter agreeing with the statements in this 8-K, attached as Exhibit 7.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1896212/000149315224014883/0001493152-24-014883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1896212/000149315224014883/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer